BlackRock
MBIO icon

BlackRock’s Mustang Bio MBIO Stock Holding History

BlackRock’s Portfolio MBIO Stock Details MBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.5K Hold
84,745
– – ﹤0.01% 5138
2026
Q1 		$61.7K Hold
84,745
– – ﹤0.01% 5075
2025
Q4 		$83.1K Hold
84,745
– – ﹤0.01% 4946
2025
Q3 		$129K Buy
84,745
+83,080
+4,990% +$148K ﹤0.01% 4778
2025
Q2 		$1.59K Hold
1,665
– – ﹤0.01% 5332
2025
Q1 		$2.08K Sell
1,665
-2
-0.1% -$8 ﹤0.01% 5298
2024
Q4 		$14.8K Hold
1,667
– – ﹤0.01% 5139
2024
Q3 		$19.6K Sell
1,667
-77
-4% -$1.27K ﹤0.01% 4938
2024
Q2 		$41.3K Sell
1,744
-238
-12% -$4.53K ﹤0.01% 4899
2024
Q1 		$103K Sell
1,982
-27
-1% -$1.72K ﹤0.01% 4719
2023
Q4 		$136K Sell
2,009
-3
-0.1% -$238 ﹤0.01% 4737
2023
Q3 		$208K Sell
2,012
-19
-0.9% -$3.69K ﹤0.01% 4667
2023
Q2 		$631K Buy
2,031
+278
+16% +$69.8K ﹤0.01% 4428
2023
Q1 		$482K Sell
1,753
-268
-13% -$110K ﹤0.01% 4538
2022
Q4 		$598K Sell
2,021
-952
-32% -$325K ﹤0.01% 4566
2022
Q3 		$1.05M Sell
2,973
-45
-1% -$20.8K ﹤0.01% 4463
2022
Q2 		$1.32M Sell
3,018
-4,557
-60% -$2.52M ﹤0.01% 4421
2022
Q1 		$5.74M Sell
7,575
-98
-1% -$80.5K ﹤0.01% 3886
2021
Q4 		$9.55M Buy
7,673
+983
+15% +$1.59M ﹤0.01% 3701
2021
Q3 		$13.5M Buy
6,690
+106
+2% +$228K ﹤0.01% 3529
2021
Q2 		$16.4M Buy
6,584
+1,271
+24% +$3.12M ﹤0.01% 3415
2021
Q1 		$13.2M Buy
5,313
+853
+19% +$2.54M ﹤0.01% 3423
2020
Q4 		$12.7M Buy
4,460
+1,353
+44% +$3.23M ﹤0.01% 3252
2020
Q3 		$7.34M Buy
3,107
+550
+22% +$1.36M ﹤0.01% 3401
2020
Q2 		$6.1M Sell
2,557
-30
-1% -$70.1K ﹤0.01% 3443
2020
Q1 		$5.2M Hold
2,587
– – ﹤0.01% 3341
2019
Q4 		$7.92M Buy
2,587
+210
+9% +$481K ﹤0.01% 3354
2019
Q3 		$5.81M Buy
2,377
+65
+3% +$178K ﹤0.01% 3436
2019
Q2 		$6.38M Buy
2,312
+1,250
+118% +$3.57M ﹤0.01% 3450
2019
Q1 		$2.71M Sell
1,062
-38
-3% -$108K ﹤0.01% 3600
2018
Q4 		$2.43M Buy
1,100
+7
+0.6% +$21.3K ﹤0.01% 3608
2018
Q3 		$4.88M Buy
1,093
+46
+4% +$230K ﹤0.01% 3512
2018
Q2 		$5.41M Buy
1,047
+1,018
+3,510% +$6.43M ﹤0.01% 3484
2018
Q1 		$237K Buy
29
+26
+867% +$221K ﹤0.01% 4176
2017
Q4 		$26K Buy
+3
New +$23.2K ﹤0.01% 4527

Other funds holding MBIO

KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $743M AUM 25.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock's MBIO Position: Q2 2026 in Review

BlackRock held its Mustang Bio (MBIO) position steady in Q2 2026 at 84,745 shares worth $59.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5138.

BlackRock first reported a position in MBIO in Q4 2017 and has held it in 35 quarters since. The position peaked at $16.4M in Q2 2021. 23 funds tracked by Wall St. Rank hold MBIO as of Q2 2026.

  • BlackRock held 84,745 shares of Mustang Bio worth $59.5K as of Q2 2026.
  • BlackRock left its Mustang Bio share count unchanged in Q2 2026.
  • Mustang Bio made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5138 holding.
  • BlackRock first reported a position in Mustang Bio in Q4 2017 and has held it in 35 quarters since.
  • BlackRock's Mustang Bio position peaked at $16.4M in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.